[Sclerosing treatment of esophageal varices].
The results of esophageal varices treatment in two groups of patients are shown. The first group consists of 351 patients who suffered an hemorrhage and were treated with sclerosing varices during the acute period or in the intervals of bleedings. The second group consists of 90 cirrhotic patients to whom a prophylactic treatment was administered. From 67 patients treated during acute hemorrhage 6 (9%) died due to hemorrhage, 6 (9%) due to hepatic failure and 1 (1.5%) due to sepsis. The 90 cirrhotic patients with prophylactic treatment were divided in 3 groups. In the first group of 30, 15 were sclerosized and 15 did not get treatment. From the second group of 32, 16 got propranolol and 16 no treatment. In the third group of 28, 14 got propranolol and were sclerosized and 14 were not treated. In all three groups with treatment hemorrhage ceased in a statistically significative manner. Surviving was the same in the treated and non-treated groups. Most patients died due to an hepatic failure.
Jorge
A D
AD
Cátedra Clínica Médica III, Facultad Ciencias Médicas, U.N.C., Mendoza, Argentina.
Milutin
C
C
Oliver
J
J
D004932:Esophageal and Gastric Varices / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000628:therapy; D006801:Humans; D006975:Hypertension, Portal / Q000150:complications; D008103:Liver Cirrhosis / Q000150:complications; D008297:Male; D011379:Prognosis; D011433:Propranolol / Q000627:therapeutic use; D012597:Sclerosing Solutions / Q000627:therapeutic use*
D012597:Sclerosing Solutions; D011433:Propranolol
Tratamiento esclerosante de las várices esofágicas.